KARDIOTOKSIČNOST VISOKE DOZE METILPREDNIZOLONA KOD BOLESNIKA SA HRONIČNOM LIMFOCITNOM LEUKEMIJOM – PRIKAZ SLUČAJA

  • Milica Apostolović Stojanović KBC "Dr Dragiša Mišović" Beograd, Klinika za internu medicinu, Odeljenje hematologije
  • Milica Radojković Kliničko-bolnički centar „Dr Dragiša Mišović”, Beograd, Medicinski fakultet, Univerzitet u Beogradu
  • Aleksandar Stojanović Institut za ortopediju „Banjica”, Beograd
  • Vladan Vukomanović Kliničko-bolnički centar „Dr Dragiša Mišović”, Beograd
DOI: https://doi.org/10.5937/smclk3-36683
Ključne reči: hronična limfocitna leukemija, atrijalna fibrilacija izazvana lekovima, visoke doze metilprednizolona

Sažetak


Uvod: Nekoliko klasa lekova mogu izazvati atrijalnu fibrilaciju (AF) kod bolesnika koji nemaju oboljenje srca, kao i pojavu atrijalne fibrilacije kod postojećeg srčanog oboljenja. AF izazvana lekovima se najčešće klinički manifestuje u vidu paroksizma. Visoke doze intravenskog metilprednizolona (VDMP) u lečenju hronične limfocitne leukemije (HLL) povezane su sa pojavom različitih neželjenih efekata, uključujući i pojavu atrijalne fibrilacije. Tačan mehanizam atrijalne fibrialcije indukovane VDMP-om nije poznat.

Prikaz slučaja: Prikazujemo slučaj bolesnika sa HLL-om, kod koga je, nakon primene visoke doze intravenskog metilprednizolona, došlo do pojave atrijalne fibrilacije.

Zaključak: Lekari bi trebalo da budu upoznati sa posebnim okolnostima u lečenju hronične limfocitne leukemije, jer AF izazvana lekom može biti neželjeni efekat koji ograničava dalju terapiju.

Reference


  1. Craig T. January, L. Samuel Wann, Hugh Calkins, Lin Y. Chen, 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019; 140:e125-e151.

  2. Falk RH. Etiology and complications of atrial fibrillation: insights from pathology studies. Am J Cardiol 1998; 82:10N-7N.

  3. Cornelis van der Hooft CS, Heeringa J, van Herpen G, et al. Drug-induced atrial fibrillation. J Am Coll Cardiol 2004; 44:2117-24.

  4. Xang X, Li X, Yuan M, Tian C, Yang Y, Wang X, Zhang X, Sun Y, He T, Han S, Chen G, Liu N, Gao Y, Hu D, Xing Y, Shang H. Anticancer Therapy-Induced Atrial Fibrillation: Electrophysiology and Related Mechanisms. Front Pharmacol. 2018; 19:1058.

  5. Aslam AK, Vasavada BC, Sacchi TJ, Khan IA. Atrial fibrillation associated with systemic lupus erythematosus and use of methylprednisolone. Am J Ther 2001; 8:303-5.

  6. Yamamura K, Ohga S, Nishiyama K, Doi T, Tsutsumi Y, Ikeda K, et al. Recurrent atrial fibrillation after high-dose methylprednisolone therapy in a girl with lupus-associated hemophagocytic syndrome. Lupus 2011; 20:871-5.

  7. Ueda N, Yoshikawa Y, Chihara M, Kawaguchi S, Niinomi Y, Yasaki T. Atrial fibrillation followingmethylprednisolone pulse therapy. Pediatr Nephrol 1988; 2: 29-31.

  8. McLuckie AE, Savage RW. Atrial fibrillation following pulse methylprednisolone therapy in an adult. Chest 1993; 104:622–3.

  9. Moretti R, Torre P, Antonello RM, Zorzon M, Cazzato G. Recurrentatrial fibrillation associated with pulse administration of high doses ofmethylprednysolone: a possible prophylactic treatment. Eur J Neurol 2000; 7:130

  10. Chikanza C, Fernandes L. Arrhythmia after pulse methylprednisolone therapy. Br J Rheumatol 1991; 30:392-3.

  11. Vazin, A., Rouzitalaba, G., Firoozifar, M., Zand, F. Intravenous Methylprednisolone, a Possible Cause of the Atrial Fibrillation. Iranian Journal of Pharmaceutical Sciences, 2010; 6(1):13-8.

  12. Fujimoto S, Kondoh H, Yamamoto Y, Hisanaga S, Tanaka K. Holter electrocardiogram monitoring in nephrotic patients during methylprednisolone pulse therapy. Am J Nephrol 1990; 10:231-6.

  13. Dogukan A, Ilkay E, Poyrazoglu OK, Gunal AI, Ozgen M, Pekdemir M. Atrial fibrillation due to oral methylprednisolone in a patient with membranoproliferstive glomerulonephritis. Acta Medica 2008; 51:63-4.

  14. Vasheghani-Farahani A, Sahraian MA, Darabi L,Aghsaie A, Minagar A. Incidence of various cardiac arrhythmias and conduction disturbancesdue to high dose intravenous methylprednisolone in patients with multiple sclerosis. J Neurol Sci 2011; 309:75-8.

  15. Jongen PJ, Stavrakaki I, Voet B, Hoogervorst E, van Munster E, Linssen WH, Sinnige LG, Verhagen WI, Visser LH, van der Kruijk R, Verheul F, Boringa J, Heerings M, Gladdines W, Lönnqvist F, Gaillard P. Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse. J Neurol. 2016; 263(8):1641-51.

  16. Jung F, DiMarco JP. Treatment strategies for atrial fibrillation. Am J Med 1998;104:272-86.

  17. Tamargo J, Caballero R, Delpón E.Expert Opin Drug Saf. 2012; 11(4):615-34.

  18. Van der Hooft CS, Heeringa J, Brusselle GG, et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med 2006; 166:1016-20.

  19. Christiansen CF, Christensen S, Mehnert F, et al. Glucocorticoid use and risk of atrial fibrillation or flutter. A population-based, case-control study. Arch Intern Med 2009; 169:1677-8.

  20. Hebb AL, Imran SA, Morris DP, Bance M, Walling S. Presentation of atrial fibrillation following oral dexamethasone treatment in a NF2 patient. Am J Otolaryngol. 2014 Sep-Oct; 35(5):678-82.

  21. Romano et al.Atrial fibrillation following therapy with high-dose i.v. methylprednisolone: A brief case-based review. Eur J Rheumatol 2017; 4:231-3.

  22. Pavičić T, Ruška B, Adamec I, Habek M. Recurrent atrial fibrillation after pulse corticosteroid treatment for a relapse of multiple sclerosis. Mult Scler Relat Disord. 2019; 32:30-2.

  23. Iqbal FM, Beeharilal PS, Sadat K, et al. Steroid induced atrial fibrillation. Compr Ther. 2008; 34:111-4.

  24. Oteri A, Bussolini A, Sacchi M, Clementi E, Zuccotti GV, Radice S. A case of atrial fibrillation induced by inhaled fluticasone propionate. Pediatrics. 2010; 126(5):e1237-41.

  25. Brian R. Overholser, John C. Lopshire and James E. Tisdale. Drug-Induced Atrial Fibrillation Yaman Kaakeh. Drugs. 2012; 72(12):1617-30.

  26. Kuppahally SS, Akoum N, Burgon NS, Badger TJ, Kholmovski EG, Vijayakumar S, Rao SN, Blauer J, Fish EN, Dibella EV, Macleod RS, McGann C, Litwin SE, Marrouche NF. Left atrial strain and strain rate in patients with paroxysmal and persistent atrial fibrillation: relationship to left atrial structural remodeling detected by delayed-enhancement MRI. Circ Cardiovasc Imaging. 2010; 3(3):231-9.

  27. Tsang TS, Barnes ME, Bailey KR, Leibson CL, Montgomery SC,Takemoto Y, Diamond PM, Marra MA, Gersh BJ, Wiebers DO, Petty GW, Seward JB. Left atrial volume: important risk marker of incident atrial fibrillation in 1655 older men and women. Mayo Clin Proc. 2001; 76:467-75.

  28. Yoon YE, Kim HJ, Kim SA et al. Left atrial mechanical function and stiffness in patients with paroxysmal atrial fibrillation. J Cardiovasc Ultrasound, 2012; 20:140-5.

  29. Henein M, Zhao Y, Henein MY, Lindqvist P. Disturbed left atrial mechanical function in paroxysmal atrial fibrillation: A speckle tracking study. Int J Cardiol, 2012; 155:437-41.

  30. Razazian, N., Hedayati, N., Moradian, N., Bostani, A., Afshari, D., Asgari, N. (2014) P wave duration and dispersion and QT interval in multiple sclerosis. Mult Scler Relat Disord; 3(5):662-5.

  31. Patton KK, Heckbert SR, Alonso A, Bahrami H, Lima JA, Burke G, Kronmal RA. N-terminal pro-B-type natriuretic peptide as a predictor of incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis: the effects of age, sex and ethnicity. Heart. 2013; 99(24):1832-6.

  32. Shanafelt TD, Parikh SA, Noseworthy PA, Goede V, Chaffee KG, Bahlo J, Call TG, Schwager SM, Ding W, Eichhorst B, Fischer K, Leis JF, Chanan-Khan AA, Hallek M, Slager SL, Kay NE. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2017; 58(7):1630-9.

  33. Ganatra S, Sharma A, Shah S, Chaudhry GM, Martin DT, Neilan TG, Mahmood SS, Barac A, Groarke JD, Hayek SS, Dani S, Venesy D, Patten R, Nohria A. Ibrutinib-Associated Atrial Fibrillation. JACC Clin Electrophysiol. 2018; 4(12):1491-1500.

Objavljeno
2022/06/29
Broj časopisa
Vol. 3 Br. 2 (2022): Srpski medicinski časopis Lekarske komore
Rubrika
Prikazi slučajeva